A maternal blood test
The test uses a blood sample from the pregnant patient, limiting the physical burden associated with specimen collection.
Healthcare & LaboratoryOASIS Health / Non-Invasive Prenatal Testing (NIPT)
PRENATAL SCREENING
NIFTY® / NIFTY® Pro
Non-Invasive Prenatal Testing (NIPT)
Clear information and careful guidance during pregnancy.
A prenatal screening test that analyses cell-free fetal DNA in maternal blood to assess the chance of selected chromosomal conditions.
From 10 weeks of pregnancy6–10 mL maternal bloodProvided through medical institutions
01 / 0501
OVERVIEW
About NIFTY® / NIFTY® Pro
NIPT is a screening test that analyses cell-free DNA in a maternal blood sample. It is not a diagnostic test such as amniocentesis or chorionic villus sampling.
OASIS provides NIFTY®, which focuses on the major trisomies, and NIFTY® Pro, which includes a broader range of analysis. The exact test scope depends on the menu offered by the medical institution.
02
FEATURES
Key features
NIFTY® and NIFTY® Pro
Options range from screening for trisomies 21, 18 and 13 to expanded menus that include additional chromosomal findings.
Results explained by a clinician
Pre- and post-test information is essential, with confirmatory testing and specialist consultation considered when appropriate.
03
SPECIFICATION
Test specification
- Test category
- Prenatal screening
- Timing
- From 10 weeks of pregnancy
- Specimen
- 6–10 mL maternal blood in a dedicated collection tube
- Method
- Cell-free DNA analysis / next-generation sequencing
- Core conditions
- Trisomies 21, 18 and 13
- Optional scope
- Sex chromosome aneuploidies, other chromosomes and selected microdeletions or duplications, depending on the menu
- Turnaround
- Approximately 20–25 business days; specimen and analysis status may affect timing
- Access
- Through participating medical institutions
Specifications and turnaround may vary according to specimen quality, transport, analytical status and the menu offered by the medical institution.
04
DETAILS
NIFTY®
The core option focuses on the major chromosomal aneuploidies.
- Trisomy 21 (Down syndrome)
- Trisomy 18 (Edwards syndrome)
- Trisomy 13 (Patau syndrome)
- Sex chromosome options vary by medical institution
NIFTY® Pro
An expanded option that analyses a wider range of chromosomal regions.
- Core trisomies
- Other autosomal aneuploidies
- Sex chromosome aneuploidies
- Selected copy-number variants, including microdeletions and duplications
Before testing
It is important to understand what the test can and cannot determine before making a personal decision.
- A high-chance result does not confirm a diagnosis
- A low-chance result cannot exclude every condition
- A result may not be available because of fetal fraction or biological factors
- Diagnostic testing may be considered after a high-chance result
05
PROCESS
Testing process
- 01
Clinical consultation
Pregnancy, medical history and testing preferences are reviewed.
- 02
Information and consent
The scope, limitations and possible next steps are explained.
- 03
Blood collection
Maternal blood is collected in a dedicated tube.
- 04
Transport and analysis
The specimen is transported and analysed under the designated workflow.
- 05
Result consultation
The medical institution explains the result and any recommended follow-up.
06
FAQ
Frequently asked questions
QCan NIPT confirm whether the fetus has a condition?＋
ANo. NIPT is a screening test. A high-chance result requires discussion with the clinician and may be followed by diagnostic testing such as amniocentesis.
QIs testing available for twin or IVF pregnancies?＋
ATesting may be possible, but eligibility and available items depend on the pregnancy. Individual consultation with a medical institution is required.
QHow long does the result take?＋
AThe expected turnaround is approximately 20–25 business days after specimen receipt. Transport, specimen quality and repeat analysis may affect this timeframe.
Important information
NIPT is not a diagnostic test. Eligibility, timing, result interpretation and the need for confirmatory testing must be discussed with the treating clinician or a genetics professional.